Wyeth Touts PE Efficacy Claims In Comments To FDA
This article was originally published in The Pink Sheet Daily
Executive Summary
As Rep. Waxman urges FDA to reexamine phenylephrine, Wyeth avers PE efficacy, submits three studies to FDA in comments.
You may also be interested in...
Avoiding GMP “Showstoppers” Keeps Manufacturers Off FDA’s “Radar”
Compliance consultants warn that certain dietary supplement good manufacturing practices violations are inspection "showstoppers" and will draw agency enforcement
Avoiding GMP “Showstoppers” Keeps Manufacturers Off FDA’s “Radar”
Compliance consultants warn that certain dietary supplement good manufacturing practices violations are inspection "showstoppers" and will draw agency enforcement
Chattem’s Financing Strategy Keeps Door Open For Acquisitions
Chattem remains in the hunt for acquisitions because its preferred financing strategy continues to be attractive even with lending activity slowed worldwide, according to President and Chief Operating Officer Bob Bosworth